|
|
|
|
LEADER |
02220 am a22003493u 4500 |
001 |
108805 |
042 |
|
|
|a dc
|
100 |
1 |
0 |
|a Suntharalingam, Kogularamanan
|e author
|
100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Chemistry
|e contributor
|
100 |
1 |
0 |
|a Koch Institute for Integrative Cancer Research at MIT
|e contributor
|
100 |
1 |
0 |
|a Suntharalingam, Kogularamanan
|e contributor
|
100 |
1 |
0 |
|a Lin, Wei
|e contributor
|
100 |
1 |
0 |
|a Johnstone, Timothy
|e contributor
|
100 |
1 |
0 |
|a Bruno, Peter Michael
|e contributor
|
100 |
1 |
0 |
|a Zheng, Yaorong
|e contributor
|
100 |
1 |
0 |
|a Hemann, Michael
|e contributor
|
100 |
1 |
0 |
|a Lippard, Stephen J.
|e contributor
|
700 |
1 |
0 |
|a Lin, Wei
|e author
|
700 |
1 |
0 |
|a Johnstone, Timothy
|e author
|
700 |
1 |
0 |
|a Bruno, Peter Michael
|e author
|
700 |
1 |
0 |
|a Zheng, Yaorong
|e author
|
700 |
1 |
0 |
|a Hemann, Michael
|e author
|
700 |
1 |
0 |
|a Lippard, Stephen J.
|e author
|
245 |
0 |
0 |
|a A Breast Cancer Stem Cell-Selective, Mammospheres-Potent Osmium(VI) Nitrido Complex
|
260 |
|
|
|b American Chemical Society (ACS),
|c 2017-05-11T14:18:32Z.
|
856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/108805
|
520 |
|
|
|a The effect of a newly developed osmium(VI) nitrido complex, 1, on breast cancer stem cells (CSCs) is reported. The complex displays selective toxicity for HMLER breast cancer cells enriched with CD44-positive, CSC-like cells over the same cells having reduced CSC character. Remarkably, 1 also reduces the proportion of CSCs within a heterogeneous breast cancer cell population and irreversibly inhibits the formation of free-floating mammospheres to an extent similar to that of salinomycin, a natural product that targets CSCs. Detailed mechanistic studies reveal that in breast cancer cells 1 induces DNA damage and endoplasmic reticulum stress, the latter being responsible for the CSC selectivity. The anti-CSC properties of 1 provide a strong impetus for the development of new metal-based compounds to target CSCs and to treat chemotherapy-resistant and relapsed tumors.
|
520 |
|
|
|a National Cancer Institute (U.S.) (Grant CA034992)
|
520 |
|
|
|a Misrock Foundation (Fellowship)
|
546 |
|
|
|a en_US
|
655 |
7 |
|
|a Article
|
773 |
|
|
|t Journal of the American Chemical Society
|